L-Arginine has a role in the L-Arginine-nitric oxide pathway in preeclampsia, where in preeclampsia, it has been known to decrease the bioavailability of nitric oxide (NO). This study analyzed the effect of L-arginine on Placental Growth Factor (PlGF) levels in mouse models with preeclampsia. This study used a true experimental design with a randomized posttest-only control group. The sample of the study was Swiss Mus musculus, divided into three groups, namely normal pregnant mice, preeclampsia models without L-arginine and preeclampsia models with Larginine. The mean serum of PlGF levels of the preeclampsia mouse models with L-Arginine was 962.431±158.211 pg/ml. This level was higher than the normal pregnant mice (947.339±208.267 pg/ml) and the preeclampsia mouse models without L-Arginine administration ( 861.985±161.960 pg/ml). There were no differences in PlGF levels between the group of normal pregnant mice and preeclampsia mice models without L-Arginine (p = 0.346). There were no significant differences between PlGF levels between the group of normal pregnant mice and the preeclampsia mouse models with L-Arginine (p = 0.865), and no significant differences were found between the groups of preeclampsia pregnant mouse models without and with L-Arginine administration (p = 0.202). Higher levels of PlGF were found in mouse models of preeclampsia with L-Arginine administration. However, there was no difference in PlGF levels between three groups.